MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esté, J. A.
Right arrow Articles by Schols, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esté, J. A.
Right arrow Articles by Schols, D.

Vol. 55, Issue 1, 67-73, January 1999

Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor

José A. Esté, Cecilia Cabrera, Erik De Clercq, Sofie Struyf, Jo Van Damme, Gary Bridger, Renato T. Skerlj, Michael J. Abrams, Geoffrey Henson, Arantxa Gutierrez, Bonaventura Clotet, and Dominique Schols

Institut de la Recerca de la SIDA-Caixa, Retrovirology Laboratory, Hospital Universitari Germans Trias i Pujol, Badalona, Spain (J.A.E., C.C., A.G., B.C.), Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium (J.A.E., E.D.C., S.S., J.V.D., D.S.), and AnorMED Inc., Langley, British Columbia, Canada (G.B., R.T.S., M.J.A., G.H.)

Bicyclams represent a novel class of selective anti-HIV inhibitors with potent activity against T-cell tropic strains of HIV. The prototype compound, the bicyclam AMD3100, has an EC50 of 1 to 10 ng/ml against different strains of HIV-1, including clinical isolates. AMD3100 was shown to interact with the CXC-chemokine receptor CXCR4, the main coreceptor used by T-cell tropic strains of HIV. Here we describe the interaction of different bicyclam derivatives with CXCR4. A close correlation (r2 = 0.7) was found between the anti-HIV potency of the bicyclams and their ability to inhibit the binding of an anti-CXCR4 monoclonal antibody or the intracellular Ca++ signal induced by the stromal cell-derived factor-1alpha , the natural ligand of CXCR4. These results indicate that the mechanism of action of bicyclams is primarily mediated by their interaction with CXCR4. The most potent interaction with CXCR4 and thus anti-HIV activity was shown by bicyclam analogs with cyclam rings composed of fourteen members that are linked by an aromatic (phenyl) bridge. Elucidating the structural requirements for receptor interaction and the site(s) of interaction of bicyclams with CXCR4 will aid in the understanding of HIV-cell fusion.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
G. Moncunill, M. Armand-Ugon, I. Clotet-Codina, E. Pauls, E. Ballana, A. Llano, B. Romagnoli, J. W. Vrijbloed, F. O. Gombert, B. Clotet, et al.
Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026
Mol. Pharmacol., April 1, 2008; 73(4): 1264 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. M. Rosenkilde, L.-O. Gerlach, S. Hatse, R. T. Skerlj, D. Schols, G. J. Bridger, and T. W. Schwartz
Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor
J. Biol. Chem., September 14, 2007; 282(37): 27354 - 27365.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. M. Whitcomb, W. Huang, S. Fransen, K. Limoli, J. Toma, T. Wrin, C. Chappey, L. D. B. Kiss, E. E. Paxinos, and C. J. Petropoulos
Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 566 - 575.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. M. Hunter, I. W. McNae, X. Liang, J. Bella, S. Parsons, M. D. Walkinshaw, and P. J. Sadler
Protein recognition of macrocycles: Binding of anti-HIV metallocyclams to lysozyme
PNAS, February 15, 2005; 102(7): 2288 - 2292.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. Princen, S. Hatse, K. Vermeire, S. Aquaro, E. De Clercq, L.-O. Gerlach, M. Rosenkilde, T. W. Schwartz, R. Skerlj, G. Bridger, et al.
Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist
J. Virol., December 1, 2004; 78(23): 12996 - 13006.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. M. Rosenkilde, L.-O. Gerlach, J. S. Jakobsen, R. T. Skerlj, G. J. Bridger, and T. W. Schwartz
Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor: TRANSFER OF BINDING SITE TO THE CXCR3 RECEPTOR
J. Biol. Chem., January 23, 2004; 279(4): 3033 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
T. Dragic
An overview of the determinants of CCR5 and CXCR4 co-receptor function
J. Gen. Virol., August 1, 2001; 82(8): 1807 - 1814.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Xiao, C. Neuveut, H. L. Tiffany, M. Benkirane, E. A. Rich, P. M. Murphy, and K.-T. Jeang
Selective CXCR4 antagonism by Tat: Implications for in vivo expansion of coreceptor use by HIV-1
PNAS, October 10, 2000; 97(21): 11466 - 11471.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. De Clercq
Inhibition of HIV Infection by Bicyclams, Highly Potent and Specific CXCR4 Antagonists
Mol. Pharmacol., May 1, 2000; 57(5): 833 - 839.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
J. Blanco, J. Barretina, G. Henson, G. Bridger, E. De Clercq, B. Clotet, and J. A. Esté
The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis
Antimicrob. Agents Chemother., January 1, 2000; 44(1): 51 - 56.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
H. F. Egberink, E. De Clercq, A. L. W. Van Vliet, J. Balzarini, G. J. Bridger, G. Henson, M. C. Horzinek, and D. Schols
Bicyclams, Selective Antagonists of the Human Chemokine Receptor CXCR4, Potently Inhibit Feline Immunodeficiency Virus Replication
J. Virol., August 1, 1999; 73(8): 6346 - 6352.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
L. O. Gerlach, R. T. Skerlj, G. J. Bridger, and T. W. Schwartz
Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor
J. Biol. Chem., April 20, 2001; 276(17): 14153 - 14160.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics